Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to date has demonstrated that patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Ledermann, Jonathan A., Pujade-Lauraine, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535754/
https://www.ncbi.nlm.nih.gov/pubmed/31205507
http://dx.doi.org/10.1177/1758835919849753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535754/
https://www.ncbi.nlm.nih.gov/pubmed/31205507
http://dx.doi.org/10.1177/1758835919849753

Ejemplares similares